U.S. Markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.1862%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.3841%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.1918%)
     
  • BTC-USD

    19,336.89
    -189.03 (-0.97%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report

·1 min read
  • After disruptions at GSK plc (NYSE: GSK), supplies of rotavirus infection vaccine in children have either run out in Kenya, Tanzania, Senegal, and Cameroon or are close, Reuters reported citing officials close to the roll-out.

  • According to the World Health Organization, up to 200,000 children die each year of contagious infection.

  • The infection causes severe, dehydrating gastroenteritis in children under five years.

  • GSK confirmed a shortfall of around 4 million doses of its Rotarix vaccine in 2022, dropping 42 million from an expected 46 million.

  • GSK acknowledged the fall in supply and said it was pursuing plans to address the deficit.

  • The company had already cut its agreed deliveries by 10 million a year for 2022-2028, Gavi, the Vaccine Alliance, said.

  • "GSK communicated to Gavi earlier this year on manufacturing challenges leading to an unplanned, short-term drop in Rotarix production for 2022, for which priority mitigation plans are fully in place," a GSK spokesperson told Reuters.

  • Gavi said there were also delays with another rotavirus vaccine, Rotavac, manufactured by Bharat Biotech, related to "regulatory procedures," although the problem is not as significant.

  • Price Action: GSK shares are down 3.17% at $38.76 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.